Comparable stake leader
ARMISTICE CAPITAL, LLC
SEC ownership of Iterum Therapeutics plc
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001659323.
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
1/13
Latest evidence
30 Jun 2026
- Public ticker
- ITRMF on OTC
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ARMISTICE CAPITAL, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
1 of 13
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ARMISTICE CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001659323
- Issuer location
- Dublin 1, Ireland
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Iterum Therapeutics plc (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
1/13
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 5%
12 rows are not safely comparable across share classes.
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-8 of 13 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 5%.
1 of 13 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 1
ARMISTICE CAPITAL, LLC
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 13 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
Reported 13D/G
· 31 Dec 2024
|
$1,820,899
1,445,158 shares
|
$0 | 31 Dec 2024 |
| Ronald Hunt |
3/4/5
Director
|
—
mixed-class rows
|
$483,028
592,954 shares
mixed-class rows
|
— | 13 Jan 2025 |
| Corey N. Fishman |
3/4/5
Chief Executive Officer, Director
|
—
mixed-class rows
|
$191,887
219,675 shares
mixed-class rows
|
— | 06 Aug 2024 |
| Michael W. Dunne |
3/4/5
Director
|
—
denominator unverified
|
$88,013
241,001 shares
|
+$2,191 | 18 Nov 2025 |
| Beth Hecht |
3/4/5
Director
|
—
denominator unverified
|
$26,375
18,839 shares
|
— | 15 Jun 2023 |
| Mark Chin |
3/4/5
Director
|
—
denominator unverified
|
$25,628
18,306 shares
|
— | 15 Jun 2023 |
| Sailaja Puttagunta |
3/4/5
Chief Medical Officer
|
—
mixed-class rows
|
$14,517
102,035 shares
mixed-class rows
|
— | 01 Dec 2023 |
| BARCLAYS PLC |
13F
Company
|
—
denominator unverified
|
$539
10,795 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$2,191.
Buys
$2,191
Insiders: 1
Sells
$0
Insiders: 0
Net
+$2,191
Shares: +6,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 6,000
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 6,000 | 0 | $2,191 | $0 | +$2,191 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-11 of 11 reporting-owner rows connected to Iterum Therapeutics plc. Open a relationship link for the CIK-to-CIK filing trail.
Rows
11
Largest Forms 3/4/5 holder
Ronald Hunt
Net 12M change
+$2,191
Latest report
18 Nov 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Ronald Hunt | Director | $483,028 | Mixed | 13 Jan 2025 | ||
| Corey N. Fishman | Chief Executive Officer, Director | $191,887 | Mixed | 06 Aug 2024 | ||
| Michael W. Dunne | Director | $88,013 | +$2,191 | +2.6% | Filing P/S | 18 Nov 2025 |
| Beth Hecht | Director | $26,375 | Mixed | 15 Jun 2023 | ||
| Mark Chin | Director | $25,628 | Mixed | 15 Jun 2023 | ||
| Sailaja Puttagunta | Chief Medical Officer | $14,517 | Mixed | 01 Dec 2023 | ||
| David G. Kelly | Director | Mixed | 15 Jun 2022 | |||
| Joseph J. Whalen | Director | Mixed | 10 Mar 2025 | |||
| Brenton K. Ahrens | Director | Mixed | 23 Dec 2022 | |||
| Christine R. Coyne | Chief Commercial Officer | Mixed | 01 Jul 2025 | |||
| Judith M. Matthews | Chief Financial Officer | Mixed | 31 Mar 2023 |
Recent insider transactions for Iterum Therapeutics plc
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Michael W. Dunne | ITRM | Ordinary Shares | Purchase | 2.55% | $2,191 | $0.3652 | 6,000 | 241,001 | 18 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.